Neurocrine Biosciences Engages Investors at Upcoming Healthcare Conferences in September 2025

Neurocrine Biosciences Engages Stakeholders Through Upcoming Investor Conferences

Neurocrine Biosciences, Inc. actively participates in the healthcare dialogue by announcing its involvement in four investor conferences scheduled for September 2025. This initiative highlights Neurocrine's commitment to transparency and engagement with investors, stakeholders, and the broader healthcare community. The company’s Chief Financial Officer, Matt Abernethy, along with other key executives, plans to present at these events, showcasing Neurocrine’s advancements in neuroscience and its ongoing dedication to addressing complex neurological conditions.

The Cantor Global Healthcare Conference kicks off Neurocrine's series of presentations on September 3, where Abernethy, Chief Commercial Officer Eric Benevich, and Vice-President of Investor Relations Todd Tushla will represent the company. This conference sets the stage for Neurocrine to share insights into its financial health and business strategy, particularly in the context of its innovative treatments for neurological disorders. Following this, the leadership team, including Chief Executive Officer Kyle Gano and Chief Medical Officer Sanjay Keswani, will address the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, emphasizing Neurocrine’s pipeline of therapies and commitment to patient care.

On September 10, Gano, Keswani, and Tushla will speak at the Baird 2025 Global Healthcare Conference, further expanding on Neurocrine's innovative approaches in treating neuroendocrine and neuropsychiatric disorders. The series concludes with a presentation at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry and Epilepsy Virtual Summit on September 17, where Gano and Tushla will discuss the latest developments in Neurocrine’s research and therapeutic strategies. Neurocrine's active participation in these conferences not only fosters investor relations but also illustrates the company's ongoing mission to alleviate patient suffering through groundbreaking scientific advancements.

In addition to these presentations, Neurocrine Biosciences continues to maintain a robust online presence, providing live webcasts of its events and replays accessible for a month after each session. This approach not only enhances accessibility for stakeholders but also reinforces Neurocrine's dedication to keeping the public informed about its progress and initiatives in the biopharmaceutical field. With over 30 years of expertise, Neurocrine remains focused on advancing treatment options for neurological disorders, striving to improve patient outcomes through innovative therapies.